Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle…
A new study led by experts at the University of Nottingham has provided new insight into how a commonly used test for colorectal cancer performs in people under 50.